RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Advanced Oncotherapy Stock

Advanced Oncotherapy EBIT 2024

Advanced Oncotherapy EBIT

-9.58 M GBP

Ticker

AVO.L

ISIN

GB00BD6SX109

WKN

A2AL9X

In 2024, Advanced Oncotherapy's EBIT was -9.58 M GBP, a -63.67% increase from the -26.37 M GBP EBIT recorded in the previous year.

The Advanced Oncotherapy EBIT history

YEAREBIT (undefined GBP)
2027e39.69
2026e19.24
2025e5.85
2024e-9.58
2023e-26.37
2022e-27.81
2021-23.74
2020-20.27
2019-20.66
2018-21.85
2017-14.49
2016-13.09
2015-7.62
2014-4.16
2013-2.12
2012-1.06
2011-0.67
2010-1.14
20091.74
2008-0.97
20072.74
20063.18
20050.31
20040.11

Advanced Oncotherapy Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Advanced Oncotherapy, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Advanced Oncotherapy from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Advanced Oncotherapy’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Advanced Oncotherapy. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Advanced Oncotherapy’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Advanced Oncotherapy’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Advanced Oncotherapy’s growth potential.

Advanced Oncotherapy Revenue, EBIT and net profit per share

DateAdvanced Oncotherapy RevenueAdvanced Oncotherapy EBITAdvanced Oncotherapy Net Income
2027e211.91 M undefined39.69 M undefined23.08 M undefined
2026e176.57 M undefined19.24 M undefined10.45 M undefined
2025e149.24 M undefined5.85 M undefined2.24 M undefined
2024e103.31 M undefined-9.58 M undefined-8.94 M undefined
2023e34.4 M undefined-26.37 M undefined-25.15 M undefined
2022e0 undefined-27.81 M undefined-38.56 M undefined
20210 undefined-23.74 M undefined-29.49 M undefined
20200 undefined-20.27 M undefined-25.3 M undefined
20190 undefined-20.66 M undefined-20.79 M undefined
20180 undefined-21.85 M undefined-21.15 M undefined
20170 undefined-14.49 M undefined-13.66 M undefined
20160 undefined-13.09 M undefined-10.35 M undefined
20150 undefined-7.62 M undefined-6.56 M undefined
20140 undefined-4.16 M undefined-7.46 M undefined
201370,000 undefined-2.12 M undefined-3.94 M undefined
2012100,000 undefined-1.06 M undefined-2.71 M undefined
20116.16 M undefined-670,000 undefined-6.49 M undefined
20103.4 M undefined-1.14 M undefined-4.09 M undefined
20093.41 M undefined1.74 M undefined-1.9 M undefined
20082.86 M undefined-970,000 undefined-1.69 M undefined
20072.12 M undefined2.74 M undefined1.35 M undefined
20061.83 M undefined3.18 M undefined680,000 undefined
20051.75 M undefined310,000 undefined-600,000 undefined
2004560,000 undefined110,000 undefined-180,000 undefined

Advanced Oncotherapy stock margins

The Advanced Oncotherapy margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Advanced Oncotherapy. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Advanced Oncotherapy.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Advanced Oncotherapy's sales revenue. A higher gross margin percentage indicates that the Advanced Oncotherapy retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Advanced Oncotherapy's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Advanced Oncotherapy's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Advanced Oncotherapy's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Advanced Oncotherapy. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Advanced Oncotherapy's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Advanced Oncotherapy Margin History

Advanced Oncotherapy Gross marginAdvanced Oncotherapy Profit marginAdvanced Oncotherapy EBIT marginAdvanced Oncotherapy Profit margin
2027e-128.57 %18.73 %10.89 %
2026e-128.57 %10.89 %5.92 %
2025e-128.57 %3.92 %1.5 %
2024e-128.57 %-9.27 %-8.66 %
2023e-128.57 %-76.65 %-73.1 %
2022e-128.57 %0 %0 %
2021-128.57 %0 %0 %
2020-128.57 %0 %0 %
2019-128.57 %0 %0 %
2018-128.57 %0 %0 %
2017-128.57 %0 %0 %
2016-128.57 %0 %0 %
2015-128.57 %0 %0 %
2014-128.57 %0 %0 %
2013-128.57 %-3,028.57 %-5,628.57 %
2012100 %-1,060 %-2,710 %
201115.42 %-10.88 %-105.36 %
201050 %-33.53 %-120.29 %
200986.51 %51.03 %-55.72 %
200885.31 %-33.92 %-59.09 %
200791.98 %129.25 %63.68 %
200695.63 %173.77 %37.16 %
200596 %17.71 %-34.29 %
200496.43 %19.64 %-32.14 %

Advanced Oncotherapy Aktienanalyse

What does Advanced Oncotherapy do?

Advanced Oncotherapy PLC is a therapeutic company in London specializing in the development of advanced and precise radiation therapy solutions. The company was founded in 2005 and has since developed a revolutionary technology that allows for the treatment of cancer cells with the highest precision and minimal to no damage to surrounding tissue. The business model of Advanced Oncotherapy aims to offer innovative technology solutions that benefit patients throughout their medical cancer treatment. The various facets of the company include research and development, production, sales and distribution, as well as clinical trials. Advanced Oncotherapy focuses on a direct customer-customer relationship by offering customers interesting treatment options tailored to the patient's needs. The flagship product of Advanced Oncotherapy is the LIGHT radiation therapy system, which is unique worldwide due to its precision, accuracy, and effectiveness in the treatment of cancer. This system allows oncologists and radiologists to perform innovative radiation therapy that promises better treatment outcomes. The LIGHT technology is based on the principles of intensity-modulated radiation therapy (IMRT) and next-generation particle therapy (NGPT). By using proton beams, the radiation therapy can be focused directly on a specific region of the body where cancer tissue is spreading. Advanced Oncotherapy offers a wide range of radiation therapy services to its customers. This includes proton accelerators (PROTON), PET/CT systems (positron emission tomography/computed tomography), CT scanners (computed tomography), and other tools and devices. The product line has been specifically developed for the precise irradiation of tumors as well as the diagnosis of cancer and other related diseases. Customers of Advanced Oncotherapy are primarily hospitals, medical centers, and health authorities. In recent years, Advanced Oncotherapy has collaborated closely with various partners such as CERN (European Organization for Nuclear Research), the Royal Marsden Hospital, University College London, and other institutions to constantly improve and further develop its technology and products. Milestones in the company's history include the CE marking for the LIGHT system and support for clinical trials by research-intensive university hospitals. The future of Advanced Oncotherapy looks promising, with a strong growth forecast for the global radiation therapy market. With an increasing demand for innovative solutions in cancer treatment, the company can look forward to a growing customer base and an increasing number of partnerships and collaborations. Advanced Oncotherapy will continue to focus on continuously optimizing its technology to provide cancer patients with the best treatment options. Advanced Oncotherapy ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Advanced Oncotherapy's EBIT

Advanced Oncotherapy's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Advanced Oncotherapy's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Advanced Oncotherapy's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Advanced Oncotherapy’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Advanced Oncotherapy stock

How much did Advanced Oncotherapy achieve in EBIT for the current year?

In the current year, Advanced Oncotherapy has achieved an EBIT of -9.58 M GBP.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Advanced Oncotherapy.

How has the EBIT of Advanced Oncotherapy developed in recent years?

The EBIT of Advanced Oncotherapy has increased by -63.672% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Advanced Oncotherapy?

The EBIT of Advanced Oncotherapy is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Advanced Oncotherapy pay?

Over the past 12 months, Advanced Oncotherapy paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Advanced Oncotherapy is expected to pay a dividend of 0 GBP.

What is the dividend yield of Advanced Oncotherapy?

The current dividend yield of Advanced Oncotherapy is .

When does Advanced Oncotherapy pay dividends?

Advanced Oncotherapy pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Advanced Oncotherapy?

Advanced Oncotherapy paid dividends every year for the past 0 years.

What is the dividend of Advanced Oncotherapy?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Advanced Oncotherapy located?

Advanced Oncotherapy is assigned to the 'Health' sector.

Wann musste ich die Aktien von Advanced Oncotherapy kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Advanced Oncotherapy from 9/11/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.

When did Advanced Oncotherapy pay the last dividend?

The last dividend was paid out on 9/11/2024.

What was the dividend of Advanced Oncotherapy in the year 2023?

In the year 2023, Advanced Oncotherapy distributed 0 GBP as dividends.

In which currency does Advanced Oncotherapy pay out the dividend?

The dividends of Advanced Oncotherapy are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Advanced Oncotherapy

Our stock analysis for Advanced Oncotherapy Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Advanced Oncotherapy Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.